Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Takeda Oncology.

Advances in™: Diagnosis and Targeting of EGFR exon 20 Insertion Mutations in NSCLC

Release Date: August 4, 2021
Expiration Date: August 4, 2022

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of non–small cell lung cancer (NSCLC), with a forward-looking perspective on how new and novel agents might impact clinical practice. The essentials of molecular testing and emerging treatment options for EGFR exon 20 insertion–positive disease will be presented in a multimedia format. A series of video interviews with an expert thought leader is integrated into text-based elements to provide clinical perspectives.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists and pulmonologists interested in the treatment of NSCLC. Pathologists, histologists, nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with NSCLC will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Depict the role of EGFR exon 20–insertion mutations in tumor biology comparative to other EGFR subtypes
  • Assess the rationale for timely and optimal molecular testing for patients with NSCLC across lines of care
  • Apply efficacy and safety results from trials evaluating patients with EGFR exon 20 insertion–mutated NSCLC to personalize application of novel emerging agents along the disease continuum

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Pasi A. Jänne, MD, PhD
Pasi A. Jänne, MD, PhD
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant/Research Support: Astellas Pharmaceuticals, AstraZenenca, Daiichi Sankyo, Puma Biotechnology, Eli Lilly Pharmaceuticals, Boehringer Ingelheim, Revolution Medicines, Takeda Oncology; Consultant: AstraZeneca, Boehringer Ingelheim, Pfizer, Roche/Genentech, Chugai Pharmaceuticals, Acea Biosciences, Ignyta, LOXO Oncology, Eli Lilly Pharmaceuticals, Araxes Pharmaceuticals, SFJ Pharmaceuticals, Voronoi, Daiichi Sankyo, Biocartis, Novartis, Sanofi, Takeda Oncology, Mirati Therapeutics, Transcenta, Silicon Therapeutics, Syndax Pharmaceuticals, Nuvalent, Bayer, Esai, Allorion Therapeutics, Accutar Biotech, Abbvie; Stock/Shareholder: Gatekeeper Pharmaceuticals, LOXO Oncology. Other Support: LabCorp; for postmarketing royalties from Dana-Farber Cancer Institute–owned intellectual property on EGFR mutations licensed to Lab Corp.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By